Atara Biotherapeutics angles for $92M, but jobs are scarce
Atara is among a new breed of “virtual” biotech startups. Such firms operate with barebones staff and outsource research and manufacturing operations to contract organizations. They are becoming increasingly common as investors seek to mitigate the huge risks of bringing drugs to market, a process that can cost as much as $1.8 billion, according to industry estimates.
Read More →Amgen seeks approval for new cholesterol drug
Amgen became the first drugmaker to seek U.S. regulatory approval for a new class of cholesterol-lowering treatments after it submitted an application to the Food and Drug Administration on Thursday for evolocumab. Thousand Oaks-based Amgen said the drug works by blocking a naturally occurring protein called PCSK9 that prevents the liver from removing LDL cholesterol, Read More →
Read More →Amgen cuts jobs at Thousand Oaks headquarters as drug focus narrows
Thousand Oaks-based biotech giant Amgen has entered a new era in which a leaner organization focuses on shepherding 10 late-stage molecules into an increasingly competitive global market. Amgen said July 29 that it will cut staff at its Conejo Valley headquarters and consolidate into fewer buildings as part of a company-wide restructuring plan that Read More →
Read More →Editorial: Large employers loosen grip on Ventura County
Half-a-dozen years ago, East Ventura County’s economy was heavily dependent on two very large employers: subprime lending giant Countrywide Financial Corp. and biotech behemoth Amgen.
Read More →Dubroff: Wall Street rattles the West Coast, shaking up Amgen and Allergan
What happens on Wall Street is having a direct impact on West Coast jobs, with indirect effects on housing and other markets.
Read More →Amgen to slash 2,400 jobs, shrink Thousand Oaks HQ
Thousand Oaks-based Amgen will cut staff at its Conejo Valley headquarters and consolidate into fewer buildings as part of a company-wide restructuring plan that will eliminate between 2,400 and 2,900 jobs and shutter facilities in Colorado and Washington. Amgen said the moves are designed to reduce operating expenses by $700 million by 2016, money that Read More →
Read More →Amgen hires former 3M exec as CFO
Amgen has hired David Meline, formerly with industrial conglomerate 3M Co., as its new chief financial officer. At 3M, Meline was responsible for the finances of a Minnesota-based company with more than $30 billion in worldwide revenues. Amgen, the world’s largest biotechnology firm, had profits of $5 billion in 2013, a 17 percent increase from Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
